ATE375331T1 - Amidderivate als inhibitoren der glycogensynthasekinase-3-beta - Google Patents

Amidderivate als inhibitoren der glycogensynthasekinase-3-beta

Info

Publication number
ATE375331T1
ATE375331T1 AT02790304T AT02790304T ATE375331T1 AT E375331 T1 ATE375331 T1 AT E375331T1 AT 02790304 T AT02790304 T AT 02790304T AT 02790304 T AT02790304 T AT 02790304T AT E375331 T1 ATE375331 T1 AT E375331T1
Authority
AT
Austria
Prior art keywords
sub
sup
alkyl
hydrogen
polyhaloc
Prior art date
Application number
AT02790304T
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Peter Jacobus Johan Buijnsters
Marc Willems
Werner Constant Joha Embrechts
Jean Fernand Armand Lacrampe
Paul Adriaan Jan Janssen
Paulus Joannes Lewi
Jan Heeres
Jonge Marc Rene De
Lucien Maria Henricus Koymans
Frederik Frans Desire Daeyaert
Michael Joseph Kukla
Hugo Geerts
Rony Maria Nuydens
Marc Hubert Mercken
Donald William Ludovici
Paul Janssen
Graziella Janssen
Jasmin Janssen
Maroussia Janssen
Herwig Janssen
Theodora Arts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE375331T1 publication Critical patent/ATE375331T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
AT02790304T 2001-11-01 2002-10-29 Amidderivate als inhibitoren der glycogensynthasekinase-3-beta ATE375331T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01204193 2001-11-01

Publications (1)

Publication Number Publication Date
ATE375331T1 true ATE375331T1 (de) 2007-10-15

Family

ID=8181176

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02790304T ATE375331T1 (de) 2001-11-01 2002-10-29 Amidderivate als inhibitoren der glycogensynthasekinase-3-beta

Country Status (21)

Country Link
US (1) US7183288B2 (de)
EP (1) EP1442019B8 (de)
JP (1) JP2005507419A (de)
KR (1) KR20050040814A (de)
CN (1) CN1582277A (de)
AT (1) ATE375331T1 (de)
AU (1) AU2002363174B2 (de)
BR (1) BR0213791A (de)
CA (1) CA2463821A1 (de)
DE (1) DE60222921T2 (de)
DK (1) DK1442019T3 (de)
EA (1) EA007578B1 (de)
ES (1) ES2294190T3 (de)
HU (1) HUP0402330A3 (de)
IL (1) IL161661A0 (de)
MX (1) MXPA04004177A (de)
NO (1) NO327097B1 (de)
NZ (1) NZ531855A (de)
PL (1) PL368917A1 (de)
PT (1) PT1442019E (de)
WO (1) WO2003037869A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2506415A1 (en) 2002-11-19 2004-06-03 Achillion Pharmaceuticals, Inc. Substituted aryl thioureas and releated compounds; inhibitors of viral replication
JP2007531753A (ja) * 2004-03-31 2007-11-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非イミダゾール系複素環式化合物
EP1734963A4 (de) 2004-04-02 2008-06-18 Merck & Co Inc Verfahren zur behandlung von menschen mit metabolischen und anthropometrischen störungen
EP2543376A1 (de) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazin Kinasehemmer
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
US7879853B2 (en) 2004-06-28 2011-02-01 Bayer Schering Pharma Ag 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP2314289A1 (de) 2005-10-31 2011-04-27 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
NZ567851A (en) 2005-11-01 2011-09-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
JP2009520811A (ja) * 2005-12-22 2009-05-28 クリスタルジェノミクス、インコーポレイテッド プロテインキナーゼ活性を阻害するアミノピリミジン誘導体、及びその製造方法並びにこれを有効成分として含む医薬組成物
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2653940C (en) 2006-05-30 2015-07-14 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
US8841334B2 (en) * 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
CA2647598A1 (en) * 2006-05-31 2007-12-06 Abbott Laboratories Compounds as cannabinoid receptor ligands and uses thereof
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN101765594A (zh) 2007-03-28 2010-06-30 雅培制药有限公司 作为大麻素受体配体的1,3-噻唑-2(3h)-亚基化合物
US7872033B2 (en) * 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
JP2010527929A (ja) * 2007-05-18 2010-08-19 アボット・ラボラトリーズ カンナビノイド受容体リガンドとしての新規な化合物
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US9193713B2 (en) * 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
EA018582B1 (ru) 2007-11-20 2013-09-30 Янссен Фармацевтика Н.В. Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н
FR2931108B1 (fr) * 2008-05-15 2011-01-07 Peugeot Citroen Automobiles Sa Limiteur de vitesse a indicateur de vitesse limite a deplacement manuel, pour vehicule automobile
EP2321341B1 (de) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
US8846730B2 (en) * 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
AU2009293319A1 (en) * 2008-09-16 2010-03-25 Abbott Laboratories Substituted benzamides as cannabinoid receptor ligands
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
PA8854001A1 (es) * 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
RS55227B1 (sr) 2010-01-22 2017-02-28 Acetylon Pharmaceuticals Inc Jedinjenja reverznog amida kao inhibitori protein deacetilaze i postupci za njihovu upotrebu
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
CN107011270A (zh) 2010-11-16 2017-08-04 阿塞蒂隆制药公司 作为蛋白质去乙酰化酶抑制剂的嘧啶羟基酰胺化合物和其使用方法
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
CN103804362A (zh) * 2012-11-12 2014-05-21 韩文毅 一类治疗糖尿病的化合物及其用途
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
EP2970119B1 (de) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Neuartige indolderivate als antidiabetika
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2015054099A1 (en) 2013-10-08 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors
US9278963B2 (en) 2013-10-10 2016-03-08 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
ES2918673T3 (es) 2013-10-24 2022-07-19 Mayo Found Medical Education & Res Tratamiento de enfermedades poliquísticas con un inhibidor de HDAC6
PE20161030A1 (es) 2013-12-03 2016-11-06 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
AU2015288060A1 (en) 2014-07-07 2017-02-09 Acetylon Pharmaceuticals, Inc. Treatment of leukemia with histone deacetylase inhibitors
CA2969790A1 (en) 2014-12-05 2016-06-09 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine
US10272084B2 (en) 2015-06-01 2019-04-30 Regenacy Pharmaceuticals, Llc Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
US10144714B2 (en) 2015-06-08 2018-12-04 Acetylon Pharmaceuticals, Inc. Methods of making protein deacetylase inhibitors
TW201718516A (zh) 2015-06-08 2017-06-01 艾斯特隆製藥公司 組蛋白去乙醯酶抑制劑之晶形
JP2019515909A (ja) 2016-04-19 2019-06-13 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 慢性リンパ性白血病の治療を目的とするｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との配合物
US11324744B2 (en) 2016-08-08 2022-05-10 Acetylon Pharmaceuticals Inc. Methods of use and pharmaceutical combinations of histone deacetylase inhibitors and CD20 inhibitory antibodies
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN110128305A (zh) * 2019-05-10 2019-08-16 天津大学 二甲双胍-甲苯磺丁脲新盐型、其制备方法及医药用途
CN116813497B (zh) * 2023-08-31 2023-11-14 天津匠新致成科技有限公司 一种酰胺类化合物及其制备方法、药物组合物和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1198551A (en) 1968-01-22 1970-07-15 Union Pharma Scient Appl New Nicotinuric Acid Derivatives
DE2334266A1 (de) 1972-07-07 1974-01-31 Hisamitsu Pharmaceutical Co Pyrido eckige klammer auf 2,3-d eckige klammer zu pyrimidin-2,4 (1h, 3h)-dione
JPS5069096A (de) 1973-10-25 1975-06-09
US5264437A (en) 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
DE69839735D1 (de) * 1997-12-15 2008-08-28 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
NZ506679A (en) 1998-03-27 2002-11-26 Janssen Pharmaceutica Nv HIV inhibiting pyrimidine derivatives
CN1312807A (zh) 1998-06-19 2001-09-12 希龙公司 糖元合成酶激酶3的抑制剂
SK287269B6 (sk) 1998-11-10 2010-05-07 Janssen Pharmaceutica N. V. Derivát pyrimidínu, jeho použitie, spôsob jeho prípravy a farmaceutická kompozícia, kombinácia a produkt s jeho obsahom
PT1169038E (pt) 1999-04-15 2012-10-26 Bristol Myers Squibb Co Inibidores cíclicos da proteína tirosina cinase

Also Published As

Publication number Publication date
NO327097B1 (no) 2009-04-20
IL161661A0 (en) 2004-09-27
ES2294190T3 (es) 2008-04-01
NO20041891L (no) 2004-05-07
US7183288B2 (en) 2007-02-27
DE60222921T2 (de) 2008-08-07
PL368917A1 (en) 2005-04-04
BR0213791A (pt) 2004-12-07
DE60222921D1 (de) 2007-11-22
HUP0402330A2 (hu) 2005-02-28
DK1442019T3 (da) 2008-01-14
NZ531855A (en) 2005-12-23
EP1442019A1 (de) 2004-08-04
US20050176713A1 (en) 2005-08-11
PT1442019E (pt) 2007-12-11
EA200400615A1 (ru) 2004-08-26
HUP0402330A3 (en) 2010-03-29
CA2463821A1 (en) 2003-05-08
AU2002363174B2 (en) 2008-09-25
MXPA04004177A (es) 2004-09-06
EP1442019B1 (de) 2007-10-10
JP2005507419A (ja) 2005-03-17
CN1582277A (zh) 2005-02-16
EA007578B1 (ru) 2006-12-29
KR20050040814A (ko) 2005-05-03
WO2003037869A1 (en) 2003-05-08
EP1442019B8 (de) 2013-10-30

Similar Documents

Publication Publication Date Title
ATE375331T1 (de) Amidderivate als inhibitoren der glycogensynthasekinase-3-beta
MXPA04004176A (es) Derivados de aminobenzamida como inhibidores de cinasa 3beta de glicogeno sintasa.
MXPA04004178A (es) Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta.
MX2009007005A (es) Pirimidinas 6-sustituidas que inhiben el virus de inmunodeficiencia humana.
TW200519115A (en) Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
AR053784A1 (es) Compuestos y derivados tetrazolicos de dibencil amina. composiciones farmaceuticas.
PE20081393A1 (es) Derivados de quinolina como inhibidores de csf-1r
WO2001055116A3 (en) Quinoline derivatives and their use as aurora 2 kinase inhibitors
WO2003024967A3 (en) Indolizines as kinase protein inhibitors
NO20080391L (no) Pyrazolbaserte LXR modulatorer
JO3429B1 (ar) مشتقات برميدينات مثبطة فيروس الايدز
CY1114908T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
TW200734322A (en) Indole derivatives exhibiting PGD2 receptor antagonism
TW200800938A (en) Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism
MXPA04002495A (es) Compuestos de imidazopiridin como moduladores del receptor 5-ht4.
MXPA04006834A (es) Compuestos de acridina y acridona terapeuticos.
TW200626561A (en) HIV inhibiting 5-substituted pyrimidines
YU58301A (sh) 2-aminopiridini koji sadrže supstituente sa kondenzovanim prstenom
MY140571A (en) Mercaptoimidazoles as ccr2 receptor antagonists
EP1057829A4 (de) Kondensierte Pyrimidinderivate und diese enthaltende pharmazeutische Zubereitungen
TW200606155A (en) Mercaptoimidazoles as CCR2 receptor antagonists
KR950704331A (ko) 세펨 화합물 및 그의 약제학적 조성물(cephem compounds and their pharmaceutical compositions)
DE60214554D1 (de) Derivate von 3-phenyl-n-(2-(4-benzyl)piperidin-1-yl)ethyl) acrylamid mit ccr-3-rezeptor antagonistischer wirkung zur verwendung bei der behandlung von entzündungen und allergischen leiden
TW200618797A (en) Isatin compounds and pharmaceutical composition comprising the same
NO20062187L (no) Furanderivat som EP4-reseptorantagonister

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1442019

Country of ref document: EP